Return to Perspectives
COVID-19 Legal Resource Guide
March 31, 2020

FDA, FTC Issue Warning Letter to Neuro XPF Over Fraudulent Coronavirus Claims for CBD Products

The FDA and FTC issued a joint warning letter to Neuro XPF regarding misleading statements about its cannabidiol (CBD) products on its website. The agencies allege that Neuro XPF claimed that CBD can prepare the human body to fight the coronavirus. According to the regulators, there is currently no competent or reliable scientific evidence that CBD prevents or treats the coronavirus and, as a result, the claims are in violation of the FD&C Act and the FTC Act. The letter requested that Neuro XPF stop marketing their products as being capable of preventing, treating or diagnosing COVID-19. Neuro XPF was given 48 hours from the date of the letter’s receipt to correct the violations or risk legal action, which could include seizure and injunction.​


View the warning letter

Authors and Editors

Related Practices

We use cookies on this website to optimize user experience and site functionality and to give you the best possible experience. We do so with your approval. The choice is up to you. Learn more.